56results about How to "Reduce the number of immunizations" patented technology

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The present invention belong to veterinary new biological medicine technology field, relates to porcine circovirus type II (PCV2) inactivated vaccine of and method for preparing same. The vaccine used seed virus is porcine circovirus type II DBN-SX07 strain, the preservation number is CGMCC No 3064, the virus strain is used as antigen preparation of inactivation by alkyl agents and emulsification by adding oil adjuvant. Using the invention provided PCV2 inactivated vaccine to immune pig can generate an uniform and effective protection force-shorting PCV2 infection windows period obviously, and prolong immune duration-reducing times of booster immunization.

The invention provides a preparation method of a bivalent vaccine by taking newcastle disease virus La Sota strain and infectious bronchitis virus N-S multi-epitope protein as antigen. To immunize 21-day-old chickens, the bivalent vaccine prepared by the method disclosed by the invention can be used for simultaneously preventing newcastle disease and nephrotropic infectious bronchitis virus infection, and the antibody level of the bivalent vaccine is higher than that of respectively immunizing by single vaccine, so that immunological stress is effectively relieved and immunity time is reduced.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a triple vaccine for feline calicivirus infection, feline infectious rhinotracheitis and feline panleukopenia as well as a preparation method and application thereof. The triple vaccine comprises antigen components and a freeze-drying protective agent, and the antigen components comprise a feline calicivirus BJ strain inactivated antigen, a feline infectious rhinotracheitis virus SH strain inactivated antigen and a feline panleukopenia virus SY strain inactivated antigen. The feline calicivirus antigen, the feline infectious rhinotracheitis virus antigen and the feline panleukopenia virus antigen are prepared by adopting a full-suspension technology, the triple inactivated freeze-dried vaccine for feline calicivirus, feline infectious rhinotracheitis and feline panleukopenia is prepared through the processes of inactivation, concentration, freeze-drying and the like, three diseases are avoided by one injection, the animal immunization frequency is reduced, the animal stress frequency is reduced, and the economic cost of feeders is greatly reduced.

The invention provides an H9N2 type flu virus-like particle vaccine for prevention and a preparation method thereof. The vaccine composition comprises H9N2 type flu virus-like particles, the virus-like particles are of the virus-like shell particle structure of the H9N2 type flu virus, and the shell particle structure capsule membrane surfaces contain one or more structural protein of the H9N2 type flu virus; the preparation method includes the steps that firstly, HA, NA and M1 gene DNA are synthesized, recombinant plasmid pFastBac-DuaL-HA-NA-M1 is constructed, the constructed recombinant plasmid is led into E.coLi competent state cell strain DH10Bac cells, the plasmid rBacmid-HA-NA-M1 is obtained through blue-white selection, transfection of SF9 insect cells is conducted, the virus-like particles are obtained, an adjuvant is dissolved in the virus-like particles, and the vaccine is obtained after incubation and centrifugal cleaning are obtained. By means of the H9N2 type flu virus-like particle vaccine, an organism can be stimulated to generate a strong immune response, and immunogenicity is high.

The invention relates to the technical field of veterinary drugs, in particular to a vaccine of swine fever-porcine contagious pleuropneumoniae bivalent subunit and a preparation method and applications thereof. The vaccine comprises classical swine fever virus E2 protein, serum type-7 actinobacillus pleuropneumoniae toxin protein ApxII, serum type-1 actinobacillus pleuropneumoniae outer membraneprotein Oml and vaccine adjuvant. The vaccine is obtained by mixing and emulsifying the proteins and the vaccine adjuvant in equal volume. The vaccine can simultaneously prevent swine fever and porcine contagious pleuropneumoniae caused by serum type-1 and type-7 porcine actinobacillus pleuropneumoniae, and has good effect and low cost.

The invention aims to prepare a chicken subunit four-combination vaccine which is capable of simultaneously preventing newcastle disease, infectious bronchitis, avian influenza, infectious bursal disease and particularly super-strong virus infection. The vaccine comprises infectious bursal disease VP2 protein with the sequence of SEQ ID NO:1, newcastle disease virus, infectious bronchitis virus and avian influenza virus. The four-combination vaccine can be applied to vaccine immunity of chickens of 21 days, can be used for simultaneously preventing the newcastle disease, the infectious bronchitis, the avian influenza and the infectious bursal disease, has immune effects similar to those of a single newcastle disease vaccine, the inactivated vaccine of the infectious bronchitis, the inactivated vaccine of the avian influenza and single infectious bursal disease vaccine, and fulfills the aims of reducing immunization frequency and lowering stress.

The invention relates to a porcine circovirus type 2, porcine reproductive and respiratory syndrome bivalent vaccine and a preparation method thereof. The bivalent vaccine is a lyophilized vaccine, and comprises a porcine circovirus type 2 SH strain inactivated virus and a respiratory syndrome virus R98 strain live virus, while an adjuvant is added into the vaccine diluent, so that the immunizing effect of the vaccine can be further improved. Immune interference does not exist among the bivalent lyophilized vaccine antigens, and the quality inspection of the vaccine finished product can achieve the quality standard of a single vaccine, and the immune protection effect of the vaccine finished product is better than that of a single vaccine; the bivalent vaccine can be used for simplifying the immune procedure, reducing immune cost and reducing the stress reaction of an immunized pig, and thus the bivalent vaccine has great market application values.

The invention aims at providing a vaccine capable of simultaneously preventing infection of newcastle disease, infectious bronchitis and infectious bursal disease, in particular to very virulent strains. The vaccine comprises a infectious bursal disease VP2 protein with sequence of SEQ ID NO:1, newcastle disease and infectious bronchitis virus. The triple vaccine is used for immunizing a 21-day chick, which can simultaneously prevent newcastle disease, infectious bronchitis and infectious bursal disease, and has similar immune effect as newcastle disease single vaccine, infectious bronchitis inactivated vaccine and infectious bursal disease single vaccine, so that the aims of reducing the number of immunization times and reducing stress are achieved.

The invention provides host bacteria, and also provides an avian influenza universal vaccine; the avian influenza universal vaccine takes spore probiotics as a mucosal delivery vector. A CTL epitope peptide of H7N9 or other type A avian influenza virus subtypes, a cytokine IL-2 and a brevibacterium mucosal immune vaccine vector are organically combined for the first time and have complementary advantages. For the H7N9, H5N1, H5N6, H7N9, H7N2, H7N3, H7N7, H9N2, H10N7 and other type A avian influenza virus subtypes, a CTL epitope antigen is designed and screened, the spore vector is used for delivery of the antigen epitope; a spore and a spore-displayed recombinant IL-2 are used as adjuvants, and the immune type and immunoreaction level are regulated.

The invention relates to a vaccine composition for preventing and/or treating porcine circovirus diseases and swine influenza and its preparation method and use. The vaccine composition comprises i, a porcine circovirus subunit antigen or a nucleic acid which is used for coding the porcine circovirus subunit antigen and can be expressed in a pig, and ii, a swine influenza virus subunit antigen or a nucleic acid which is used for coding the swine influenza virus subunit antigen and can be expressed in a pig. The invention also relates to a nucleic acid molecule, a recombinant plasmid and a host cell for treating and/or preventing two types of pig diseases.

The invention belongs to the molecular biology field, and discloses an optimized PCV2d ORF2 gene and a preparation method of virus-like particles of the optimized PCV2d ORF2 gene. After a coding genesequence for coding porcine circovirus 2d subtype Cap proteins is optimized, an expression engineering bacteria expression system is constructed and is used for expressing the Cap proteins. Expressionbacteria is capable of expressing a large number of dissoluble and active porcine circovirus 2d subtype Cap proteins under a proper expression condition, the expressed proteins are purified by virtueof a monoclonal antibody column, and then the high-purity and high-concentration Cap proteins are obtained and are capable of forming the virus-like particles. According to the preparation method, efficient soluble expression of the porcine circovirus 2d subtype full-length Cap proteins in a prokaryotic expression system is realized, the operation is simple, the cost is low, the prepared monoclonal antibody column can be repeatedly used, and the Cap proteins obtained through purification are high in concentration and purity, are capable of spontaneously forming the virus-like particles, havegood immunogenicity and are suitable for industrial application.

The invention provides fullerene derivatives, the fullerene derivatives are fullerol represented by a formula of C60OxHy (x is less than 50 and more than or equal to y; y is more than 10 and less than or equal to x) or fullerene carboxyl derivatives represented by a formula of C60(C(COOH)2)n (n is an integer from 1 to 4), and the diameter range of nano particles of the fullerene derivatives in a solvent is from 1 to 400 nm. The invention also provides applications of a vaccine adjuvant of the fullerene derivatives in the vaccine field; the vaccine adjuvant has a good safety, can prominently improve the vaccine immunogenicity through different immunity ways, and has a very large application prospect.

The invention provides a preparation method for a monoclonal antibody of riemerella anatipestifer. The method comprises the following specific steps: (1) expanding the culture of the riemerella anatipestifer, inactivating formaldehyde, and then preparing suspension by using PBS to complete antigen preparation; (2) mixing the newly prepared antigen with a freund's complete adjuvant uniformly and stirring for 4 hours until a mixture is emulsified, then performing subcutaneous injection on mice, mixing the newly prepared antigen with the freund's incomplete adjuvant uniformly and stirring for 4 huntil a mixture is emulsified after two weeks of immunization, performing subcutaneous injection on the mice again to obtain immunized mice after one week of immunization, and detecting antibody titer is 1 to 6400; (3) performing cell fusion on the spleen cells of the immunized mice and SP2/0 cells; 4) performing positive screening and cloning on fusion cells in step (3). According to the method,the antibody titer is increased by improving the immune effect, so that the immunization times are reduced, thereby achieving the effects of saving time and reducing materials.

The invention discloses a porcine circovirus, porcine pseudorabies virus and mycoplasma triple inactivated vaccine which comprises an antigen and a vaccine adjuvant, the antigen is composed of a porcine circovirus type 2 antigen, a porcine pseudorabies virus antigen and a mycoplasma antigen, the porcine circovirus type 2 antigen is a purified, concentrated and inactivated porcine circovirus type 2 protein antigen solution, and the content of Cap protein is more than or equal to 160 [mu]g/ml; the porcine pseudorabies virus antigen is a purified, concentrated and inactivated porcine pseudorabies virus protein antigen solution, and the content of the Cap protein is more than or equal to 160 [mu]g/ml; the mycoplasma antigen is an inactivated mycoplasma protein antigen solution, and the content of the Cap protein is more than or equal to 160 [mu]g/ml; and the vaccine adjuvant is composed of a water-based high-molecular polymer adjuvant and a composite polysaccharide immunopotentiator. Foreign protein is removed through clarification filtration and ultrafiltration concentration, and the side reaction probability of the vaccine is greatly reduced; and three-proofing can be achieved through one needle, so that the number of immunization times and stress are reduced. The method is economical and practical, the immunization procedure is simplified, and the epidemic prevention cost is reduced.